Outcomes for patients (LDAC vs vosaroxin randomization). (A) AML LI-1: overall survival (no CR). (B) AML LI-1: overall survival from CR. (C) AML LI-1: survival from relapse. (D) AML LI-1: relapse-free survival. (E) AML LI-1: overall survival. AML LI-1, UK National Cancer Research Institute LI-1 trial; exp., expected; obs., observed.